Medical Affairs vs Commercial vs Market Access: Which Healthcare Path in 2026

Three professionals walk out of the same PharmD program. One takes an MSL role at AstraZeneca and is making $218,000 within two years. Another joins a biotech commercial team, rides a launch into a rare disease indication, and is at $280,000 in base by year four. The third builds HEOR expertise, gets recruited to lead payer evidence strategy at a mid-sized oncology company, and is fielding VP-level offers at $340,000 before they hit 40.

Same degree. Completely different trajectories. The difference was not talent. It was knowing which track to pick, and when.

The pharma and biotech job market in 2025 was brutal broadly, with biopharma layoffs rising 47% year over year and approximately 42,700 employees affected. But the pain was not evenly distributed. As Artech and PharmaPayWatch data both confirm, demand in clinical, regulatory, and commercial areas, including Medical Affairs, was more resilient than early-stage R&D and bench science throughout the downturn. Heading into 2026, a recovery is underway, driven by M&A activity ($220 billion in life sciences transactions by end of November 2025), pre-launch hiring waves, and a structural shift in which functions are considered mission-critical.

If you are a pharma or biotech professional trying to figure out which of the three major post-clinical tracks actually scales, this is the map.

The Three Tracks: A Framework Before the Details

Medical Affairs, Commercial, and Market Access are often described as three sides of the same launch strategy. In practice, they require fundamentally different skill sets, attract different personality profiles, and have ceiling heights that vary by company size, therapeutic area, and timing in the product lifecycle. Understanding the distinctions before you pick one matters as much as executing well once you are in.

Medical Affairs is the scientific bridge between the company and the clinical community. It includes Medical Science Liaisons (MSLs), Medical Directors, Medical Strategy leads, Real World Evidence (RWE) managers, and the growing field of digital medical engagement. The work is science-forward, relationship-driven, and field-based for most IC roles. It requires an advanced clinical or scientific degree (MD, PharmD, PhD) and rewards people who can communicate complex data to physician audiences without crossing the line into promotional activity.

Commercial encompasses brand marketing, sales, sales leadership, business analytics, and market development. It is the revenue engine. Commercial roles attract operators who want to drive revenue directly, manage field teams, build launch strategies, and see a clear line between their work and business outcomes. The ceiling is high, the pressure is high, and the gatekeeping for entry is lower than Medical Affairs in terms of degree requirements, but higher in terms of business track record.

Market Access is the function that determines whether a drug gets on formulary, at what price, and for which patients. It includes Health Economics and Outcomes Research (HEOR), pricing and reimbursement strategy, payer relations, policy engagement, and Real World Evidence for access. It is the fastest-growing of the three functions in terms of strategic importance, largely because the Inflation Reduction Act (IRA) in the U.S. and evolving HTA requirements globally have turned payer evidence into a company survival skill, not a support function.

Sources: PharmaPayWatch (Sep 2025–Mar 2026 job posting analysis), Glassdoor 2025/2026, PharmaDiversity Blog 2025, Smith Hanley Executive Recruiting 2025, MSL Society 2025 Salary Survey. Base salary only; excludes bonus, equity, and carry. Chart by Archer Careers.

Medical Affairs: The Science Track That Actually Pays

Medical Affairs has evolved from a defensive function (keeping the sales force out of trouble with compliant scientific content) into a genuine strategic driver of launch success and pipeline validation. In 2026, it sits at the center of evidence generation, KOL strategy, and real-world data design, which makes it relevant at every stage of a drug's lifecycle from Phase II through post-marketing.

The anchor role is the Medical Science Liaison. Based on 1,148 MSL job postings analyzed by PharmaPayWatch from September 2025 through March 2026, individual contributor MSLs cluster between $175,000 and $225,000 in base, with a median of $184,000. Management positions command a median of $226,000. Among companies with multiple MSL postings, GSK offers the highest median at $248,000, followed by Genentech at $230,000 and AstraZeneca at $218,000. The companies currently hiring most aggressively for MSLs: AbbVie (165 postings), AstraZeneca (132), Bristol Myers Squibb (123), Johnson and Johnson (113), and GSK (105).

The MSL role is not the ceiling of Medical Affairs. It is the entry point. The progression runs from MSL to Regional MSL Manager to Director of Medical Affairs to VP of Medical Affairs, with Director-level roles running $130,000 to $200,000 in base per Reddit ChubbyFIRE data (plus 30% bonus and RSU allocation), and VP positions at $200,000 to $300,000 base with 40-50% bonus structures. Above that, Chief Medical Officers at commercial-stage biotechs frequently hit total comp above $500,000 once equity is included.

Medical Affairs is also growing in scope. PharmaPayWatch's data shows roles such as Real World Evidence Manager, Medical Evidence Lead, and Medical Strategy Director becoming increasingly common. Digital Medical Affairs, covering virtual engagement models and omnichannel scientific content, is adding a new category of hires that pharma did not explicitly staff five years ago.

Who should pick this track: PharmD, PhD, or MD with genuine scientific depth in a therapeutic area and strong communication instincts. The MSL role is high-travel and relationship-intensive. If you are motivated by deep scientific exchange, like building long-term relationships with physician thought leaders, and want to stay close to clinical practice without being in it, Medical Affairs is the right fit. If you want to manage revenue lines or structure commercial deals, it is the wrong fit.

The credential that moves the needle: Therapeutic area depth in oncology, immunology, rare disease, or neurology. MSLs in complex, high-competition TAs command a significant premium and are far more portable across companies than generalists. Oncology and rare disease MSLs are the most sought after, partly because the HCP landscape is highly concentrated (50 oncologists can move a drug) and companies compete hard for those relationships.

Commercial: High Ceiling, Highest Variance

Commercial is the broadest of the three tracks, and the one with the most internal divergence. A pharmaceutical sales specialist at a primary care company and a VP of Marketing at a rare disease biotech are both technically in Commercial, but they live in completely different worlds in terms of compensation, complexity, and career leverage.

At the IC level, pharmaceutical sales specialists average $162,000 in total compensation per Glassdoor (2025), with top earners in specialty and oncology exceeding $270,000 including commission. In oncology specifically, where territory size is small and product prices are enormous, base salaries for senior sales roles can exceed $225,000 before incentive compensation. The variance is large because commission-heavy structures mean a great territory with a strong product can produce total comp two or three times a mediocre one.

Brand marketing and commercial strategy roles do not carry the same commission upside, but they carry better P&L ownership and a clearer path to VP and executive roles. Marketing Directors in pharma run $200,000 to $250,000 in base at large companies. VP of Commercial at a mid-sized biotech with a launch-stage asset is typically $280,000 to $400,000 base, with equity packages that can be meaningful if the company exits or grows into a blockbuster. At major companies, Smith Hanley data shows Director-level commercial analytics roles consistently at or above $200,000, Senior Directors at $250,000 and above, and VPs at $400,000 or greater base at large pharma.

The commercial function in 2026 is being reshaped by AI and the shift to omnichannel engagement. Clarkston Consulting's 2026 Pharma Commercial Operations Tech Trends report identified 2026 as the year of shift from AI experimentation to operationalization, with commercial field teams being enabled by predictive modeling for patient finding, AI-assisted medical training, and commercial governance systems for data quality. This means commercial roles increasingly require analytical fluency alongside traditional launch execution skills.

The most valuable current signal in commercial is the pre-launch hiring wave. As Kemp's Connections noted in mid-2025, companies with drug approvals pending are rebuilding commercial teams before PDUFA dates, often from a smaller base than they had pre-layoff, which means they are hiring into roles with real scope. Companies that cut commercial headcount in 2023 and 2024 are discovering they do not have enough people to launch. That mismatch is where the best commercial opportunities exist right now.

Among active hirers in commercial leadership heading into 2026: AstraZeneca (announcing up to $50 billion in U.S. manufacturing and R&D investment through 2030), Regeneron (expanding across immunology and oncology on the back of Dupixent's continued growth), Johnson and Johnson (investing over $55 billion in U.S. research, technology, and production), and a wave of mid-sized oncology and rare disease biotechs preparing for first launches.

Who should pick this track: People who want to own revenue and move fast. Commercial rewards decisive operators who are comfortable with ambiguity, can manage up and across in a matrix organization, and are genuinely motivated by business outcomes, not just scientific exchange. An MBA is helpful but not required. What is required is commercial instincts that show up in your track record.

The credential that moves the needle: Launch experience in a specialty or rare disease product. A single successful launch on a high-profile asset is worth more than five years on an established primary care brand. If you are earlier in your career, getting on a launch team, even in a supporting role, should be a deliberate career decision.

Market Access: The Fastest-Growing Strategic Function

Market access is having its moment, and that moment shows no signs of reversing. The Inflation Reduction Act gave Medicare the authority to negotiate prices for high-expenditure drugs, with negotiated maximum fair prices taking effect starting in 2026 for the first selected drugs, and expanding to more drugs in 2027, 2028, and 2029. Outside the U.S., European HTA reform, the UK's VPAG scheme, and Canada's updated PMPRB guidelines are creating a global environment where payer evidence is no longer optional. It is the deciding factor in whether a drug generates the revenue it was modeled to produce.

As Guidehouse's 2025 analysis bluntly stated: "If there's no access, there's no script. Even the slickest commercial strategy will become expensive theater if a drug is mispriced, non-formulary, outside of treatment guidelines, or lacking a reasonable medical policy." The function that prevents that outcome is Market Access, which is why it is being funded and hired at a rate that neither Commercial nor Medical Affairs is matching right now in strategic importance at the executive level.

The core roles in Market Access run from HEOR Analyst (building cost-effectiveness models and budget impact analyses) through Payer Evidence Strategist, Pricing and Reimbursement Manager, Market Access Director, and VP of Global HEOR. The salary trajectory is among the steepest in pharma. Director-level HEOR and Market Access roles run $200,000 to $250,000, and VP HEOR positions at global companies are regularly in the $320,000 to $400,000 range before total comp. The complexity of the work, which requires fluency in health economics, statistics, payer policy, clinical evidence, and strategic negotiation simultaneously, creates genuine scarcity that drives compensation above equivalent management levels in Commercial.

A major hiring catalyst in market access is the rise of outcomes-based contracts. Xtalks's 2026 HEOR analysis noted that more than 30 state Medicaid programs used CMS's Cell and Gene Therapy Access Model in 2025 to implement outcomes-based agreements for sickle cell gene therapies, where payment is tied to clinically meaningful patient outcomes. Structuring, modeling, and managing those contracts requires a new generation of HEOR professionals who can sit at the table with payers as financial counterparts, not just scientific submitters.

Demand for Real World Evidence professionals continues to expand within market access. HealthVerity and Claritas Rx partnered in October 2025 to link de-identified claims, EMR, lab, and specialty pharmacy data specifically to give commercial, RWE, and HEOR teams better visibility into access barriers, speed-to-therapy, and adherence. That infrastructure investment signals where payer strategy is heading: toward living RWE platforms that continuously update the value story, not static dossiers submitted at launch.

Who should pick this track: Analytically oriented professionals with background in health economics, epidemiology, public health, or outcomes research, and the ability to translate quantitative findings into strategic recommendations for executive and payer audiences. An MPH, PharmD with outcomes research focus, PhD in health services research, or economics background are all credible entry points. The consulting pathway into market access is also well-traveled: three to five years at a pricing/access consulting firm (IQVIA, Evidera, Precision AQ, Putnam Associates, Analysis Group) is one of the fastest ways to build the HEOR toolkit and exit into an industry principal-level role.

The credential that moves the needle: Direct experience with HTA submissions, Medicare negotiation preparation, or outcomes-based contract design. The IRA has created a sub-specialty of its own around CMS negotiation strategy that did not exist at scale before 2023. Professionals who have lived through that process, or who can credibly represent having done so, are being recruited specifically for it.

The Layoff Context: Which Track Is Most Durable

The 2025 downturn was instructive. Across more than 42,700 layoffs at companies including Novo Nordisk (9,000), Bayer (4,450 in nine months), BMS (2,200+), and dozens of smaller biotechs, the pattern was consistent: bench scientists, early R&D, and generalist commercial sales forces were cut first. Specialized functions, including MSLs, HEOR directors, regulatory affairs leads, and commercial analytics teams with deep product-line knowledge, were significantly more durable.

Novartis filed a WARN notice for 58 U.S. medical affairs employees between late 2025 and mid-2026, which was notable specifically because it was notable at all. Medical Affairs cuts at major companies are comparatively rare and tend to be targeted at specific TA realignments rather than broad headcount reductions. Takeda laid off 243 field-based commercial employees in 2025 as part of its $1.26 billion restructuring, but that specific cut targeted commodity primary care sales positions, not specialty commercial leadership.

The durability order in a downturn, based on observed patterns: Market Access is most protected (payer evidence cannot be outsourced away quickly and IRA compliance requires it), Medical Affairs follows (MSLs are relationship assets that take years to rebuild), and broad commercial sales is most vulnerable at the IC level (easiest to ramp down and up with contract sales organizations). Senior commercial leadership and launch-critical commercial roles are protected.

For 2026, industry analysts at PharmaPayWatch and Pharmanow collectively predict a gradual hiring rebound concentrated in exactly the roles that were most durable: regulatory, clinical, and commercial, with market access specifically seeing the benefit of continued IRA implementation complexity. Companies that cut too deeply in 2024 and 2025 are discovering they lack the internal capability to manage submissions, support launches, and run payer negotiations, and they are now hiring back.

Source: PharmaPayWatch analysis of 1,148 MSL job postings, September 2025–March 2026. Chart by Archer Careers.

How to Actually Choose

The right track depends on three things that are specific to you: your degree and clinical background, your personality type and what motivates your best work, and where you are in your career relative to where the leverage is.

If you have an MD or PharmD and enjoy clinical science over business mechanics, Medical Affairs is the natural fit. The MSL role is the most accessible entry point for clinicians transitioning out of practice or direct patient care. The compensation is strong at entry, the travel is manageable, and the path to Director and VP of Medical Affairs is structured enough to navigate. The caveat is that Medical Affairs tends to be slower and more deliberate in advancement than Commercial, and the VP-level financial upside at public companies lags behind what a strong commercial operator can make.

If you are business-oriented, motivated by P&L ownership, and want to be directly accountable for revenue, Commercial is the track. The entry into specialty or rare disease commercial roles from other industries, consulting, or academia is harder than Medical Affairs (the network gatekeeping is real), but the ceiling once inside is among the highest in pharma. The key is getting to a launch-stage company early in your career, even at a lower level, because launch experience compounds across every subsequent role.

If you have analytical depth, an economics or public health background, and want to work on the most intellectually complex problems in the industry, Market Access is the best long-term bet. The IRA alone has created a multi-year demand signal for people who understand how Medicare price negotiation, HTA submissions, and outcomes-based contracting interact with portfolio strategy. The compensation ceiling at the VP level is above both Medical Affairs and general Commercial. The consulting entry route is especially viable here: two to four years at an access-focused consulting firm builds the toolkit faster than almost any other path.

The professionals navigating these decisions most successfully are the ones who have done the positioning work before they apply. They know which function they are targeting, which companies in their therapeutic area are hiring for it, and exactly how their existing experience translates to the specific language of that function. When a VP of Medical Affairs at AbbVie reads your application, it takes fifteen seconds to tell whether you understand what MSLs actually do or you just want to work in pharma. The specificity of your positioning is the entire job search.

That translation work, mapping your clinical, scientific, or analytical background into the precise positioning language of the function you are targeting, is exactly where most strong candidates lose time they do not need to lose. It is also where the right guidance cuts that timeline in half.

Ready to make your next move?

Archer Careers helps pharma and biotech professionals land roles across Medical Affairs, Commercial, and Market Access at top companies. From resume optimization and LinkedIn positioning to precision targeting of pre-launch and launch-stage biotechs, we handle the search so you can focus on the work.

Book a free 30-minute strategy call at hirearcher.com